Amicus Therapeutics is a cutting-edge biopharmaceutical company that is leading the way in the treatment of rare and orphan diseases. They were founded in 2002 and are headquartered in New Jersey. There are several important things to know about this company.
- They are Leading the Way in Fighting Orphan Diseases
Orphan diseases are those that typically affect less than 200,000 individuals nationwide. However, there are thousands of these types of diseases worldwide that can potentially affect millions of individuals (https://www.crunchbase.com/organization/amicus-therapeutics). Amicus Therapeutics is on the front lines of technology and innovation when it comes to finding treatments for many of these rare diseases. They combine the latest breakthroughs in scientific research with clinical programs and expert commercial organization.
- They have Several Exciting Products in the Pipeline
They are currently developing exciting products and therapies to treat diseases such as Epidermolysis Bullosa, Pompe disease, and Fabry disease. Amicus Therapeutics are working to help those suffering from these difficult and often rare diseases (YahooFinance). The FDA has recently given confirmation that Amicus Therapeutics can submit a drug application that is completely new. This is specifically for their oral precision medication named migalastat that will be used to treat Fabry disease. This advancement in treatment will help thousands of individuals in the United States who are suffering from Fabry disease.
- They are an International Company
Amicus Therapeutics are located around the world. They now can be found in Germany, France, Italy, Spain, and the Netherlands. Their international headquarters are in the United Kingdom. Even though Amicus Therapeutics is a small company, they are quickly growing and expanding on a global level. This expansion around the world reflects the dedication of Amicus Therapeutics and their desire to provide the best treatments possible.
Amicus Therapeutics are continuing to provide innovative technology in an ongoing effort to develop breakthrough medications and treatments for a variety of genetic diseases. By expanding overseas and increasing the number of dedicated individuals they employ, they will continue to provide the best treatments possible for those struggling with rare diseases.